B Stančák

Cellular senescence in aging and age-related disease: from mechanisms to therapy

A global view of pulmonary hypertension

Obesity and inflammation: the linking mechanism and the complications

Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema

C-Reactive Protein

Higher Inflammatory Marker Levels in Older Persons: Associations With 5-Year Change in Muscle Mass and Muscle Strength

Role for Interleukin-6 in COPD-Related Pulmonary Hypertension

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

Cellular senescence: from physiology to pathology

Pulmonary hypertension in COPD

A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease

Plasma C-Reactive Protein and Endothelin-1 Level in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension

Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Diseases and the Heart

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

Hypoxia-Inducible Factor 1α Is a Critical Downstream Mediator for Hypoxia-Induced Mitogenic Factor (FIZZ1/RELMα)–Induced Pulmonary Hypertension

Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).

Systemic Inflammation in Patients With COPD and Pulmonary Hypertension